# Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy. The BLADE study.

- 3 Bergamini M<sup>1</sup>, Dalla Volta A<sup>1</sup>, Palumbo C<sup>2</sup>, Zamboni S<sup>3</sup>, Triggiani L<sup>4</sup>, Zamparini M<sup>1</sup>, Laganà M<sup>1</sup>, Rinaudo L<sup>5</sup>, Di
- Meo N<sup>6</sup>, Caramella I<sup>1</sup>, Bresciani R<sup>7</sup>, Valcamonico F<sup>1</sup>, Borghetti P<sup>4</sup>, Guerini A<sup>4</sup>, Farina D<sup>6</sup>, Antonelli A<sup>8</sup>, Simeone C<sup>3</sup>, Mazziotti G<sup>9,10</sup>, Berruti A<sup>1</sup>.
- 1.Medical Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological
   Sciences and Public Health, University of Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
- 8 2.Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore
  9 Della Carità Hospital, Novara, Italy.
- 3.Urology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciencesand Public Health, University of Brescia, Brescia, Italy.
- 4.Radiation Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological
   Sciences and Public Health, University of Brescia, Brescia, Italy.
- 14 5.Tecnologie Avanzate S.r.l., Turin, Italy.
- 6.Radiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences
   and Public Health, University of Brescia, Brescia, Italy.
- 7.Division of Biotechnology, Department of Molecular and Translational Medicine (DMTM), University ofBrescia, Brescia, Italy.
- 8.Urology Unit, AOUI Verona, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of
   Verona, Verona, Italy.
- 21 9. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy.
- 10. Endocrinology, Diabetology and Medical Andrology Unit, Metabolic Bone Diseases and Osteoporosis
- 23 Section, IRCCS Humanitas Research Hospital, Rozzano-Milan Italy.
- 24

### 25 Correspondence to:

- 26 Gherardo Mazziotti
- 27 Department of Biomedical Sciences
- 28 Humanitas University
- 29 Via Rita Levi Montalcini 4
- 30 20072 Pieve Emanuele, Milan
- 31 Italy
- 32
- 3334 Alberto Dalla Volta
- 35 Medical Oncology Unit
- 36 ASST-Spedali Civili
- 37 Piazzale Spedali Civili 1
- 38 25123 Brescia
- 39 Italy
- 40
- 41
- 42 Key words: prostate cancer patients, androgen deprivation, FSH, body composition, bone health NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 44 Abstract

- 45 Background: Amongst its extragonadal effects, Follicle-Stimulating Hormone (FSH) has an impact on body
- composition and bone metabolism. Since androgen deprivation therapy (ADT) has a profound impact on 46
- 47 circulating FSH concentrations, this hormone could potentially be implicated in the changes of fat body
- 48 mass (FBM), lean body mass (LBM) and bone fragility induced by ADT. The objective of this study is to
- 49 correlate FSH serum levels with body composition parameters, bone mineral density (BMD) and bone
- 50 turnover markers at baseline conditions and after 12 months of ADT.
- 51 Methods: 29 consecutive non-metastatic prostate cancer (PC) patients were enrolled from 2017 to 2019 in
- 52 a phase IV study. All patients underwent administration of the Luteinizing Hormone-Releasing Hormone
- 53 antagonist degarelix. FBM, LBM and BMD were evaluated by dual-energy x-ray absorptiometry at baseline
- 54 and after 12 months of ADT. FSH, alkaline phosphatase (ALP) and C-terminal telopeptide of type I collagen
- 55 (CTX) were assessed at baseline and after 6 and 12 months. For outcome measurements and statistical 56 analysis, T-test or sign test and Pearson or Spearman tests for continuous variables were used when
- 57 indicated.
- 58 Results: At baseline conditions, a weak, non-significant, direct relationship was found between FSH serum
- 59 levels and FBM at arms (r=0.36) and legs (r=0.33). Conversely, a stronger correlation was observed between
- FSH and total FBM (r=0.52, p=0.006), fat mass at arms (r=0.54, p=0.004) and fat mass at trunk (r=0.45, 60
- 61 p=0.018) assessed after 12 months. On the other hand, an inverse relationship between serum FSH and
- 62 appendicular lean mass index (ALMI)/FBM ratio was observed (r=0.64, p=0.001). This is an ancillary study of
  - 63 a prospective trial and this is the main limitation.

64 *Conclusions*: FSH serum levels after ADT could have an impact on body composition, in particular on fat 65 body mass. Therefore, FSH could be a promising marker to monitor the risk of sarcopenic obesity and 66 cardiovascular complications in PC patients undergoing ADT.

- 67 Funding: this research was partially funded by Ferring Pharmaceuticals. The funder had no role in 68 design and conduct of the study, collection, management, analysis, and interpretation of the data 69 and in preparation, review, or approval of the manuscript.
- 70
- 71 Clinical trial number: clinicalTrials.gov NCT03202381, EudraCT Number 2016-004210-10.
- 72

### 73 Introduction

74 Recent preclinical and clinical studies have shown that Follicle-Stimulating Hormone (FSH) exerts effects 75 beyond those on gonadal tissue, which have been known for a long time (Lizneva et al. 2019). In the animal 76 model, FSH has been observed to stimulate osteoclastic activity and therefore to exert a negative role on 77 bone mass (Sun et al. 2006; Zaidi et al. 2023; Gera et al. 2022). Furthermore, FSH was found to have a 78 positive action on adipocytes and the blockade of FSH induced by antibodies against FSH receptor caused 79 an increase in bone mass and a reduction of body fat (Liu et al. 2017; Rojekar et al. 2023). These preclinical 80 data were confirmed in clinical studies. Large epidemiologic data have shown significant reductions in bone 81 mineral density (BMD) and high resorption rates  $\sim$ 2-3 years prior to menopause, when FSH serum levels 82 are increasing, which is also associated with increased body weight and visceral adiposity (Thurston et al. 83 2009; Senapati et al. 2014). A longitudinal study involving post-menopausal women has shown that 84 increases in circulating FSH levels were associated with greater increases in the percentage of total body 85 fat, total body fat mass and subcutaneous adipose tissue (Mattick et al. 2022). Moreover, clinical studies 86 have found that FSH is also involved in the modulation of lean mass. A large cohort study of 87 perimenopausal women showed that increased FSH concentrations were associated with increasing fat 88 mass and decreasing lean mass measured by bioelectrical impedance analysis (Sowers et al. 2007). Another 89 recent prospective study showed that the indicators of sarcopenia were strongly associated with

90 gonadotropins levels, especially in older men (Guligowska et al. 2021). The impact of FSH on body medRxiv preprint doi: https://doi.org/10.1101/2023.10.24.23297490; this version posted October 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 91 composition may at least partially explain the observed correlation between FSH levels and the risk of cardiovascular events (Munir et al. 2012; Celestino Catão Da Silva et al. 2013; El Khoudary et al. 2016). 92
- 93 Studies clarifying the relationship among FSH, body composition measures and BMD in prostate cancer (PC) 94 patients are lacking. Likewise, the interaction between the variation of FSH serum levels and the
- 95 modification of these parameters in PC patients undergoing androgen deprivation therapy (ADT) is not
- 96 known.
- 97 We recently conducted the BLADE study (Bone mineral mAss Dexa dEgarelix), a prospective phase IV study
- 98 designed to obtain explorative information on dual-energy x-ray absorptiometry (DXA) measurement
- 99 changes in lean body mass (LBM) and fat body mass (FBM) in patients with non-metastatic PC treated with
- 100 degarelix. Data on changes in total LBM and FBM and on the impact of degarelix on BMD and bone
- 101 turnover markers were recently published (Palumbo et al. 2021; Palumbo et al. 2022).
- 102 Here we analyse the association of FSH with DXA-assessed FBM, LBM and BMD and bone turnover markers
- 103 at baseline and after degarelix administration in the patients enrolled in the BLADE study.
- 104

### 105 **Patients and methods**

- 106 Trial design and endpoints
- 107 BLADE is a single-centre, prospective, interventional phase IV study (clinicalTrials.gov NCT03202381,
- 108 EudraCT Number 2016-004210-10) conducted at the Prostate Cancer Unit of the Azienda Socio Sanitaria
- Territoriale degli Spedali Civili and Università degli Studi of Brescia. The study was carried out in accordance 109
- with the Declaration of Helsinki Principles and Good Clinical Practices and was approved by the Ethics 110
- 111 Committee of Brescia (approval number NP2540). All patients provided a written informed consent. Male
- 112 patients with histologically confirmed PC without bone metastasis at bone scintigraphy, judged eligible to
- 113 ADT according to current guidelines recommendations (Cornford et al. 2017; Mottet et al. 2017) after a
- 114 multidisciplinary discussion, were enrolled. Eligibility criteria have been published elsewhere (Palumbo, et
- al. 2021). Degarelix was administered as a subcutaneous injection with a starting dose of 240 mg, followed 115
- 116 by a maintenance dose of 80 mg every 28 days. After 12 months, treatment with degarelix was continued
- 117 as clinically indicated. DXA measurements for assessing BMD and body composition parameters were
- performed at baseline and after 12 months, using Hologic QDR-4500W instrumentation (Hologic 118
- 119 Corporation, Waltham, Massachusetts).
- 120 Assessment of regional lean body mass and fat body mass by dual x-ray absorptiometry
- 121 DXA measurements related to whole body DXA scans were extracted from Apex Software version 3.4.
- 122 The densitometric image of each patient was divided, following the manufacturer's instructions, into
- 123 different body districts, including arms, legs, trunk, head and other derived regions, such as the android and 124 gynoid zone.
- 125 BMD, bone mineral content (BMC), Fat Free Mass and Fat mass were assessed for every region of interest,
- where Fat Free Mass was provided by the software in terms of lean soft tissue plus BMC. Despite the lean 126
- 127 mass measured by DXA counts also skin, connective tissue and some lean components within the adipose
- 128 tissue (Visser et al. 1999), it still correlates highly with computed tomography and magnetic resonance
- 129 imaging measurements and represents a good approximation of the real muscle mass (Buckinx et al. 2018).
- 130 Other DXA derived body composition parameters, such as fat mass index (FM/H2) (FMI), appendicular lean
- 131 mass index (ALM/H2) (ALMI) and Trunk/Appendicular ratio, were then calculated to complete the analysis
- 132 and the patient characterization.

#### 133 Circulating bone turnover markers

- 134 Blood chemistry and bone turnover markers: alkaline phosphatase (ALP) and C-terminal telopeptide of type
- I collagen (CTX) were assessed at baseline, 6 and 12 months. CTX serum levels were measured using the 135
- 136 ElectroChemiLuminescenceAssay (ECLIA) kit Elecsys beta-CrossLaps/serum (Roche Diagnostic, Germany)
- using Cobas e411instruments (Roche); normal ranges were < 0.704 ng/ml (men of the age between 50-70), 137
- < 0.854 ng/ml (men > 70) with a repeatability CV% of 2.6. Bone-ALP serum levels were determined in a 138
- 139 twostep procedure. Briefly, total ALP serum activity was measured using the colorimetric method ALP2
- 140 (Roche) using Cobas c701 instruments (Roche); normal ranges were 50-116 U/L +/- 0.6 with a repeatability
- CV% of 0.7. Samples were then subjected to electrophoretic separation to separate the different ALP 141
- 142 isoforms using the G26 automated system (Sebia, France) equipped with the Interlab specific kit (Italy).
- Bone-ALP activity was calculated as fraction of the total ALP activity related to the percentage of 143
- 144 densitometric analysis of the electrophoretic migration

#### 145 Statistical analysis

- 146 The normal distribution of continuous variables was tested with the Shapiro-Wilk test. Differences between
- 147 parameters at baseline and 12 months were computed as percentage changes. To test if these changes
- were significantly different from 0 we used one sample t-test, or alternatively the non-parametric sign test. 148
- 149 Correlations between variables either at baseline and 12 months were expressed as Pearson's r (or 150 alternatively with Spearman R, for variables not normally distributed).
- 151 We considered a significant threshold of p < 0.05, and to control for possible false positive results we
- applied the Bonferroni correction ( $p' = \frac{p}{\nu'}$ , where k is the number of hypotheses tested). Given that Type I 152
- errors cannot decrease (the whole point of Bonferroni adjustments) without inflating type II errors 153 154 (Perneger 1998), significant results in the raw test but which do not remain so after correction will still be 155 mentioned.
- 156 Statistics were performed using R and SPSS (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, 157 Version 23.0. Armonk, NY: IBM Corp.)
- 158

#### Results 159

160 Twenty-nine patients were included in the BLADE study and their characteristics have been described 161 elsewhere (Palumbo, et al. 2022). The consort diagram is reported in supplementary material (Figure 1S). Mean FSH serum levels at baseline conditions were 11.9 UI/L (95% Confidence Intervals [CIs]: 7.6 to 16.3). 162 163 Mean FSH serum levels significantly decreased to 1.45 UI/L (95% Cls: 1.01 to 1.89) after 6 months of 164 degarelix treatment and to 2.4 UI/L (95% CIs: 1.4 to 3.4) after 12 months. The corresponding percent changes were -77.59% (95% Cls: -86.20 to -68.87) and -59.7% (95% Cls: -80.3 to -39.1, p <0.001) (Figure 1). 165 166 Data on changes in body composition parameters, BMD and bone turnover markers have been published 167 elsewhere (Palumbo, et al. 2021; Palumbo, et al. 2022; Dalla Volta et al. 2023). Correlations between FSH

- 168 changes and changes in body composition parameters, BMD and bone turnover markers were not
- 169 statistically significant, so these data are not presented.
- 170 Relationship between FSH serum levels and body composition, BMD and bone turnover markers at baseline
- At baseline conditions no relationship was found between FSH serum levels and the following DXA-derived parameters: BMD at left hip and spine, total FBM, total LBM, lean mass at arms and legs, ALMI, ALMI/FBM ratio and android/gynoid ratio. No correlation was also found between FSH serum levels and serum levels of either ALP or CTX. A direct relationship, although not significant, was found between FSH serum levels
- 175 and FBM at arms (r=0.36) and legs (r=0.33) (**Table 1**).
- Relationship between FSH serum levels and body composition, BMD and bone turnover markers after 12
   months of degarelix treatment
- 178 The correlation between circulating FSH levels at 6 and 12 months, bone turnover markers evaluated at the 179 same time, BMD and body composition parameters assessed after 12 months is shown in **Table 2**. FSH
- 180 serum levels assessed after 6 months of degarelix administration showed a direct relationship with total
- 181 FBM (r=0.49, p=0.008) and with fat mass evaluated at arms (r=0.53, p=0.004), trunk (r=0.48, p=0.009) and
- legs (r=0.45, p=0.015). By contrast, FSH serum levels after 6 months of treatment showed an inverse
- relationship with ALMI/FBM ratio (r=-0.58, p=0.001). FSH measured after 12 months maintained a
- significant relationship with total FBM (r=0.52, p=0.006) (**Figure 2A**), fat mass at arms (r=0.54, p=0.004)
- 185 (Figure 2B) and fat mass at trunk (r=0.45, p=0.018) (Figure 2C). The relationship between FSH and fat mass
- at legs lost the statistical significance (r=0.33, p=0.089), while the inverse relationship with ALMI/FBM ratio
   was confirmed (r=0.64, p=0.001) (Figure 2D).
- 188

### 189 Discussion

ADT in PC patients leads to an increase in fat mass and to a decrease in lean mass, thus increasing the risk

- of sarcopenic obesity. In addition, ADT has also a negative impact on skeletal fragility, which increases the
- risk of fractures. During the recent years, there has been consistent evidence that alterations in body composition could contribute to determine skeletal fragility in patients under ADT, such as well
- demonstrated in other forms of male hypogonadism (Vena et al. 2022). However, the determinants of
- altered body composition in male hypogonadism and in ADTs have not been completely defined. As a
- 196 matter of fact, low testosterone values do not seem to be the only determinant of sarcopenic obesity in
- 197 males with hypogonadism. In this context, FSH values might play a role. In fact, amongst its extragonadal
- 198 effects, FSH directly affects adipogenesis, lean mass and bone turnover (Liu, et al. 2017; Rojekar, et al.
- 199 2023; Zaidi, et al. 2023; Gera, et al. 2022).
- As demonstrated in other studies prospectively evaluating circulating FSH levels after treatment with Luteinizing Hormone-Releasing Hormone (LHRH) agonists and antagonists (Klotz et al. 2008), degarelix
- administration consistently reduced FSH values. Therefore, it is reasonable to hypothesize that this
- hormone is involved in the mechanisms that underlie ADT impact on body composition and skeletal
- 204 fragility.

This ancillary analysis of the BLADE study shows that FSH serum levels correlated with fat mass in basal
 conditions, albeit not significantly. However, either total fat mass and fat mass in the upper limbs and trunk
 significantly correlated with FSH values after 12 months of degarelix therapy.

Even more interesting, when assessed after degarelix, FSH levels inversely correlated with ALMI/FBM ratio,
 a parameter that identifies patients at high risk for sarcopenic obesity. These data suggest that sexual
 hormones counteract FSH effect on body composition at baseline conditions, whereas this effect becomes
 more evident after ADT.

- 212 It is noteworthy that FSH values and body composition parameters after 12 months of degarelix therapy
- 213 achieved a significant correlation, despite the narrow range of FSH levels (Figure 1). According to these
- 214 data, small changes in FSH can result in significant changes in body composition in a condition of androgen
- 215 and estrogen deprivation.
- It is known that one of the most noticeable differences of LHRH-antagonists compared to LHRH-agonists 216
- 217 are FSH levels during therapy, which are mildly higher with LHRH-agonists compared to LHRH-antagonists.
- 218 According to our data, PC patients treated with LHRH-antagonists may experience less body composition
- 219 changes due to lower FSH residual values (Klotz, et al. 2008; Margel et al. 2019; Abufaraj et al. 2021).
- 220 Unlike other settings, FSH values before and after degarelix did not correlate with either BMD or bone 221 turnover markers.
- 222 To our knowledge, this is the first study showing an association between circulating FSH levels and body 223 composition in PC patients undergoing ADT. However, this study suffers from all the limitations of ancillary 224 studies. Therefore, the results obtained are to be considered as hypothesis-generating and cannot be 225 generalized.
- 226 In conclusion, the findings of this study suggest that FSH serum levels after ADT could impact body 227 composition - fat body mass in particular - in PC patients undergoing ADT.
- 228 Of course further investigation is required to establish the association between FSH serum levels, measured 229 during ADT, and sarcopenic obesity risk in PC patients. However, this is an area of great interest.
- 230 FSH could be a promising marker in monitoring PC patients during ADT in order to identify those who are 231 more vulnerable and at greater risk of cardiovascular complications.
- 232

#### 233 **Statements**

- 234 Ethical approval: the study was carried out in accordance with the Declaration of Helsinki Principles and
- 235 Good Clinical Practices and was approved by the Ethics Committee of Brescia (approval numberNP2540).
- 236 All patients provided a written informed consent.
- 237
- Funding: this research was partially funded by Ferring Pharmaceuticals. The funder had no role in 238
- 239 design and conduct of the study, collection, management, analysis, and interpretation of the data
- 240 and in preparation, review, or approval of the manuscript.
- 241

242 Conflict of interest statement: Alberto Dalla Volta received grants from Janssen Cylag, Ipsen, support for 243 attending meetings and fee for board from Janssen Cylag; Luca Triggiani received honoraria from Astellas, 244 Janssen and Bayer, support for attending meeting from Janssen; Luca Rinaudo is affiliated with Tecnologie 245 Avanzate S.r.l., the author has no financial interests to declare; Paolo Borghetti received honoraria for 246 lectures from Astrazeneca and Roche; Andrea Guerini received support for attending meeting from Elekta; 247 Davide Farina received consulting fees from Siemens Healthineers; Alessandro Antonelli received payments 248 for clinical trial from Janssen, fees for advisory board from Astra Zeneca, Ipsen, Photocure, Teleflex; 249 Gherardo Mazziotti received fee for preceptorship from Amgen UCB; Alfredo Berruti received consulting 250 fee from Ferring Pharmaceuticals; Marco Bergamini, Carlotta Palumbo, Stefania Zamboni, Manuel 251 Zamparini, Marta Laganà, Nunzia Di Meo, Irene Caramella, Roberto Bresciani, Francesca Valcamonico and 252 Claudio Simeone declare that they have no conflict of interest.

253	
254	Acknowledgements: the authors are grateful to the following associations: AOB (Associazione
255	Oncologica Bresciana) and FIRM-Onlus (Fondazione Internazionale di Ricerca in Medicina Onlus) for
256	the continuous support.
257	
258 259 260 261 262 263	References Abufaraj, M., T. Iwata, S. Kimura, A. Haddad, H. Al-Ani, L. Abusubaih, M. Moschini, A. Briganti, P. I. Karakiewicz, and S. F. Shariat. 2021. "Differential Impact of Gonadotropin-Releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials." <i>Eur Urol</i> 79, no. 1 (Jan): 44-53. <u>https://dx.doi.org/10.1016/j.eururo.2020.06.002</u> .
264 265 266 267 268 269 270	<ul> <li>Buckinx, F., F. Landi, M. Cesari, R. A. Fielding, M. Visser, K. Engelke, S. Maggi, E. Dennison, N. M. Al-Daghri, S. Allepaerts, J. Bauer, I. Bautmans, M. L. Brandi, O. Bruyère, T. Cederholm, F. Cerreta, A. Cherubini, C. Cooper, A. Cruz-Jentoft, E. McCloskey, B. Dawson-Hughes, J. M. Kaufman, A. Laslop, J. Petermans, J. Y. Reginster, R. Rizzoli, S. Robinson, Y. Rolland, R. Rueda, B. Vellas, and J. A. Kanis. 2018. "Pitfalls in the Measurement of Muscle Mass: A Need for a Reference Standard." <i>J Cachexia Sarcopenia Muscle</i> 9, no. 2 (04): 269-278. <u>https://dx.doi.org/10.1002/jcsm.12268</u>.</li> </ul>
271 272 273 274 275	Celestino Catão Da Silva, D., A. Nogueira De Almeida Vasconcelos, J. Cleto Maria Cerqueira, D. De Oliveira Cipriano Torres, A. C. Oliveira Dos Santos, H. De Lima Ferreira Fernandes Costa, and L. O. Bregieiro Fernandes Costa. 2013. "Endogenous Sex Hormones Are Not Associated with Subclinical Atherosclerosis in Menopausal Women." <i>Minerva Ginecol</i> 65, no. 3 (Jun): 297-302.
276 277 278 279 280 281	Cornford, P., J. Bellmunt, M. Bolla, E. Briers, M. De Santis, T. Gross, A. M. Henry, S. Joniau, T. B. Lam, M. D. Mason, H. G. van der Poel, T. H. van der Kwast, O. Rouvière, T. Wiegel, and N. Mottet. 2017. "Eau-Estro-Siog Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer." <i>Eur Urol</i> 71, no. 4 (04): 630-642. <a href="https://dx.doi.org/10.1016/j.eururo.2016.08.002">https://dx.doi.org/10.1016/j.eururo.2016.08.002</a> .
282 283 284 285 286 287 288	<ul> <li>Dalla Volta, A., C. Palumbo, S. Zamboni, G. Mazziotti, L. Triggiani, M. Zamparini, F. Maffezzoni, L. Rinaudo, M. Bergamini, N. Di Meo, I. Caramella, F. Valcamonico, P. Borghetti, A. Guerini, D. Farina, A. Antonelli, C. Simeone, and A. Berruti. 2023. "Heterogeneity in Regional Changes in Body Composition Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: Potential Impact on Bone Health-the Blade Study." <i>J Endocrinol Invest</i> (Jul 17). https://dx.doi.org/10.1007/s40618-023-02150-z.</li> </ul>
289 290 291 292 293 294	<ul> <li>El Khoudary, S. R., N. Santoro, H. Y. Chen, P. G. Tepper, M. M. Brooks, R. C. Thurston, I. Janssen, S. D. Harlow, E. Barinas-Mitchell, F. Selzer, C. A. Derby, E. A. Jackson, D. McConnell, and K. A. Matthews. 2016. "Trajectories of Estradiol and Follicle-Stimulating Hormone over the Menopause Transition and Early Markers of Atherosclerosis after Menopause." <i>Eur J Prev Cardiol</i> 23, no. 7 (May): 694-703. <u>https://dx.doi.org/10.1177/2047487315607044</u>.</li> </ul>
295 296 297 298	Gera, S., T. C. Kuo, A. A. Gumerova, F. Korkmaz, D. Sant, V. DeMambro, K. Sudha, A. Padilla, G. Prevot, J. Munitz, A. Teunissen, M. M. T. van Leent, T. G. J.M Post, J. C. Fernandes, J. Netto, F. Sultana, E. Shelly, S. Rojekar, P. Kumar, L. Cullen, J. Chatterjee, A. Pallapati, S. Miyashita, H. Kannangara, M.

Bhongade, P. Sengupta, K. Ievleva, V. Muradova, R. Batista, C. Robinson, A. Macdonald, S.

299

300 301 302	Hutchison, M. Saxena, M. Meseck, J. Caminis, J. Iqbal, M. I. New, V. Ryu, S. M. Kim, J. J. Cao, N. Zaidi, Z. A. Fayad, D. Lizneva, C. J. Rosen, T. Yuen, and M. Zaidi. 2022. "Fsh-Blocking Therapeutic for Osteoporosis." <i>Elife</i> 11 (Sep 20). <u>https://dx.doi.org/10.7554/eLife.78022</u> .
303 304 305 306 307	Guligowska, A., Z. Chrzastek, M. Pawlikowski, M. Pigłowska, H. Pisarek, K. Winczyk, and T. Kostka. 2021. "Gonadotropins at Advanced Age - Perhaps They Are Not So Bad? Correlations between Gonadotropins and Sarcopenia Indicators in Older Adults." <i>Front Endocrinol (Lausanne)</i> 12: 797243. <u>https://dx.doi.org/10.3389/fendo.2021.797243</u> .
308 309 310 311 312	<ul> <li>Klotz, L., L. Boccon-Gibod, N. D. Shore, C. Andreou, B. E. Persson, P. Cantor, J. K. Jensen, T. K. Olesen, and F. H. Schröder. 2008. "The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group Phase Iii Study in Patients with Prostate Cancer." <i>BJU Int</i> 102, no. 11 (Dec): 1531-8. <u>https://dx.doi.org/10.1111/j.1464-410X.2008.08183.x</u>.</li> </ul>
<ul> <li>313</li> <li>314</li> <li>315</li> <li>316</li> <li>317</li> <li>318</li> <li>319</li> <li>320</li> </ul>	<ul> <li>Liu, P., Y. Ji, T. Yuen, E. Rendina-Ruedy, V. E. DeMambro, S. Dhawan, W. Abu-Amer, S. Izadmehr, B. Zhou, A. C. Shin, R. Latif, P. Thangeswaran, A. Gupta, J. Li, V. Shnayder, S. T. Robinson, Y. E. Yu, X. Zhang, F. Yang, P. Lu, Y. Zhou, L. L. Zhu, D. J. Oberlin, T. F. Davies, M. R. Reagan, A. Brown, T. R. Kumar, S. Epstein, J. Iqbal, N. G. Avadhani, M. I. New, H. Molina, J. B. van Klinken, E. X. Guo, C. Buettner, S. Haider, Z. Bian, L. Sun, C. J. Rosen, and M. Zaidi. 2017. "Blocking Fsh Induces Thermogenic Adipose Tissue and Reduces Body Fat." <i>Nature</i> 546, no. 7656 (06 01): 107-112. <a href="https://dx.doi.org/10.1038/nature22342">https://dx.doi.org/10.1038/nature22342</a>.</li> </ul>
321 322 323 324	Lizneva, D., A. Rahimova, S. M. Kim, I. Atabiekov, S. Javaid, B. Alamoush, C. Taneja, A. Khan, L. Sun, R. Azziz, T. Yuen, and M. Zaidi. 2019. "Fsh Beyond Fertility." <i>Front Endocrinol (Lausanne)</i> 10: 136. <u>https://dx.doi.org/10.3389/fendo.2019.00136</u> .
325 326 327 328 329 330	<ul> <li>Margel, D., A. Peer, Y. Ber, L. Shavit-Grievink, T. Tabachnik, S. Sela, G. Witberg, J. Baniel, D. Kedar, W. C. M. Duivenvoorden, E. Rosenbaum, and J. H. Pinthus. 2019. "Cardiovascular Morbidity in a Randomized Trial Comparing Gnrh Agonist and Gnrh Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease." <i>J Urol</i> 202, no. 6 (Dec): 1199-1208. https://dx.doi.org/10.1097/JU.0000000000384.</li> </ul>
331 332 333 334 335	Mattick, L. J., J. W. Bea, L. Singh, K. M. Hovey, H. R. Banack, J. Wactawski-Wende, J. E. Manson, J. L. Funk, and H. M. Ochs-Balcom. 2022. "Serum Follicle-Stimulating Hormone and 5-Year Change in Adiposity in Healthy Postmenopausal Women." <i>J Clin Endocrinol Metab</i> 107, no. 8 (07 14): e3455-e3462. <u>https://dx.doi.org/10.1210/clinem/dgac238</u> .
336 337 338 339 340 341 342	<ul> <li>Mottet, N., J. Bellmunt, M. Bolla, E. Briers, M. G. Cumberbatch, M. De Santis, N. Fossati, T. Gross, A. M. Henry, S. Joniau, T. B. Lam, M. D. Mason, V. B. Matveev, P. C. Moldovan, R. C. N. van den Bergh, T. Van den Broeck, H. G. van der Poel, T. H. van der Kwast, O. Rouvière, I. G. Schoots, T. Wiegel, and P. Cornford. 2017. "Eau-Estro-Siog Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent." <i>Eur Urol</i> 71, no. 4 (04): 618-629. https://dx.doi.org/10.1016/j.eururo.2016.08.003.</li> </ul>
343 344 345	Munir, J. A., H. Wu, K. Bauer, J. Bindeman, C. Byrd, I. M. Feuerstein, T. C. Villines, and A. J. Taylor. 2012. "The Perimenopausal Atherosclerosis Transition: Relationships between Calcified and Noncalcified

medRxiv preprint doi: https://doi.org/10.1101/2023.10.24.23297490; this version posted October 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

preprint (which was not certified by peer review) is the author/funder, who has g	franted medRxiv a license to display the pre
perpetuity.	
It is made available under a CC-BY 4.0 Internat	tional license.

346 347	Coronary, Aortic, and Carotid Atherosclerosis and Risk Factors and Hormone Levels." <i>Menopause</i> 19, no. 1 (Jan): 10-5. <u>https://dx.doi.org/10.1097/gme.0b013e318221bc8d</u> .
348 349 350 351 352 353	<ul> <li>Palumbo, C., A. Antonelli, L. Triggiani, A. Dalla Volta, F. Maffezzoni, S. Zamboni, P. Borghetti, L. Rinaudo, F. Valcamonico, R. Maroldi, S. M. Magrini, C. Simeone, A. Berruti, and Collaborators. 2021. "Changes in Body Composition and Lipid Profile in Prostate Cancer Patients without Bone Metastases Given Degarelix Treatment: The Blade Prospective Cohort Study." <i>Prostate Cancer Prostatic Dis</i> 24, no. 3 (09): 852-859. <u>https://dx.doi.org/10.1038/s41391-021-00345-0</u>.</li> </ul>
354 355 356 357 358 359	<ul> <li>Palumbo, C., A. Dalla Volta, S. Zamboni, G. Mazziotti, M. Zamparini, L. Triggiani, P. Borghetti, F. Maffezzoni, R. Bresciani, L. Rinaudo, F. Valcamonico, D. Farina, S. M. Magrini, A. Antonelli, C. Simeone, and A. Berruti. 2022. "Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients without Bone Metastases. The Blade Study." <i>J Clin Endocrinol Metab</i> (Aug 16). https://dx.doi.org/10.1210/clinem/dgac489.</li> </ul>
360 361 362	Perneger, T. V. 1998. "What's Wrong with Bonferroni Adjustments." <i>BMJ</i> 316, no. 7139 (Apr 18): 1236-8. https://dx.doi.org/10.1136/bmj.316.7139.1236.
363 364 365 366 367 368	<ul> <li>Rojekar, S., A. R. Pallapati, J. Gimenez-Roig, F. Korkmaz, F. Sultana, D. Sant, C. M. Haeck, A. Macdonald, S. M. Kim, C. J. Rosen, O. Barak, M. Meseck, J. Caminis, D. Lizneva, T. Yuen, and M. Zaidi. 2023.</li> <li>"Development and Biophysical Characterization of a Humanized Fsh-Blocking Monoclonal Antibody Therapeutic Formulated at an Ultra-High Concentration." <i>Elife</i> 12 (Jun 19). https://dx.doi.org/10.7554/eLife.88898.</li> </ul>
369 370 371 372	Senapati, S., C. R. Gracia, E. W. Freeman, M. D. Sammel, H. Lin, C. Kim, R. J. Schwab, and G. W. Pien. 2014. "Hormone Variations Associated with Quantitative Fat Measures in the Menopausal Transition." <i>Climacteric</i> 17, no. 2 (Apr): 183-90. <u>https://dx.doi.org/10.3109/13697137.2013.845876</u> .
373 374 375 376	Sowers, M., H. Zheng, K. Tomey, C. Karvonen-Gutierrez, M. Jannausch, X. Li, M. Yosef, and J. Symons. 2007. "Changes in Body Composition in Women over Six Years at Midlife: Ovarian and Chronological Aging." <i>J Clin Endocrinol Metab</i> 92, no. 3 (Mar): 895-901. <u>https://dx.doi.org/10.1210/jc.2006-1393</u> .
377 378 379 380 381	<ul> <li>Sun, L., Y. Peng, A. C. Sharrow, J. Iqbal, Z. Zhang, D. J. Papachristou, S. Zaidi, L. L. Zhu, B. B. Yaroslavskiy, H. Zhou, A. Zallone, M. R. Sairam, T. R. Kumar, W. Bo, J. Braun, L. Cardoso-Landa, M. B. Schaffler, B. S. Moonga, H. C. Blair, and M. Zaidi. 2006. "Fsh Directly Regulates Bone Mass." <i>Cell</i> 125, no. 2 (Apr 21): 247-60. <u>https://dx.doi.org/10.1016/j.cell.2006.01.051</u>.</li> </ul>
382 383 384 385 386	Thurston, R. C., M. R. Sowers, B. Sternfeld, E. B. Gold, J. Bromberger, Y. Chang, H. Joffe, C. J. Crandall, L. E. Waetjen, and K. A. Matthews. 2009. "Gains in Body Fat and Vasomotor Symptom Reporting over the Menopausal Transition: The Study of Women's Health across the Nation." <i>Am J Epidemiol</i> 170, no. 6 (Sep 15): 766-74. <u>https://dx.doi.org/10.1093/aje/kwp203</u> .
387 388 389 390 391	<ul> <li>Vena, W., F. Carrone, A. Delbarba, O. Akpojiyovbi, L. C. Pezzaioli, P. Facondo, C. Cappelli, L. Leonardi, L. Balzarini, D. Farina, A. Pizzocaro, A. G. Lania, G. Mazziotti, and A. Ferlin. 2022. "Body Composition, Trabecular Bone Score and Vertebral Fractures in Subjects with Klinefelter Syndrome." <i>J Endocrinol Invest</i> (Aug 28). <u>https://dx.doi.org/10.1007/s40618-022-01901-8</u>.</li> </ul>

392

Visser, M., T. Fuerst, T. Lang, L. Salamone, and T. B. Harris. 1999. "Validity of Fan-Beam Dual-Energy X-Ray
 Absorptiometry for Measuring Fat-Free Mass and Leg Muscle Mass. Health, Aging, and Body
 Composition Study--Dual-Energy X-Ray Absorptiometry and Body Composition Working Group." J
 Appl Physiol (1985) 87, no. 4 (Oct): 1513-20. https://dx.doi.org/10.1152/jappl.1999.87.4.1513.

397

- Zaidi, M., S. M. Kim, M. Mathew, F. Korkmaz, F. Sultana, S. Miyashita, A. A. Gumerova, T. Frolinger, O.
  Moldavski, O. Barak, A. Pallapati, S. Rojekar, J. Caminis, Y. Ginzburg, V. Ryu, T. F. Davies, D. Lizneva,
  C. J. Rosen, and T. Yuen. 2023. "Bone Circuitry and Interorgan Skeletal Crosstalk." *Elife* 12 (Jan 19).
  https://dx.doi.org/10.7554/eLife.83142.
- 402

403

## 1

### TABLE 1

#### 2 Table 1 – Baseline relationships between FSH serum levels and BMD, bone turnover markers and body 3 composition parameters.

4

		FSH
	Correlation coefficient	р
TOT BMD	.240	.218
BMD LEFT HIP	.229	.240
BMD L2-L4	.148	.453
СТХ	115	.560
BONE ALP	.001	.997
TOT Fat (g)	.274	.158
Arm Fat (g)	.363	.058
Leg Fat (g)	.330	.087
Head Fat (g)	.228	.244
Trunk Fat (g)	.249	.202
TOT Lean (g)	.216	.270
Arm Lean (g)	.166	.400
Leg Lean (g)	.197	.315
Head Lean (g)	.250	.199
Trunk Lean (g)	.190	.333
ALMI (Appendicular Lean/Ht <sup>2</sup> )	.269	.167
ALMI/FBM	184	.349
Android/Gynoid Ratio	024	.902

7

FSH: follicle-stimulating hormone; TOT: total; BMD: bone mineral density; CTX: C-terminal telopeptide of type I collagen; ALP:

alkaline phosphatase; ALMI: appendicular lean mass index; Ht<sup>2</sup>: height squared; FBM: fat body mass.

8 Data are Spearman R. 1

### TABLE 2

- 2 
   Table 2 – Relationships between FSH serum levels and BMD, bone turnover markers and body composition
- 3 parameters after 12-months degarelix treatment.
- 4

		FSH at 6 months		FSH at 12 months
	Correlation	р	Correlation	р
	coefficient	-	coefficient	
TOT BMD	039	.843	107	.595
BMD L2-L4	.102	.604	040	.844
BMD LEFT HIP	.030	.881	044	.829
СТХ	.051	.796	.055	.785
BONE ALP	.174	.376	.227	.256
TOT Fat (g)	.490	.008	.518	.006
Arm Fat (g)	.532	.004	.541	.004
Leg Fat (g)	.454	.015	.328	.089
Head Fat (g)	.187	.341	.093	.644
Trunk Fat (g)	.483	.009	.452	.018
TOT Lean (g)	.029	.885	036	.859
Arm Lean (g)	.041	.837	.028	.889
Leg Lean (g)	176	.371	285	.149
Head Lean (g)	.086	.663	006	.977
Trunk Lean (g)	.161	.414	.021	.916
ALMI (Appendicular	229	.241	265	.181
Lean/Ht <sup>2</sup> )				
ALMI/FBM	581	.001*	604	.001*
Android/Gynoid Ratio	.142	.472	.231	.246

5 6

FSH: follicle-stimulating hormone; TOT: total; BMD: bone mineral density; CTX: C-terminal telopeptide of type I collagen; ALP:

7 alkaline phosphatase; ALMI: appendicular lean mass index; Ht<sup>2</sup>: height squared; FBM: fat body mass.

8 9 Data are Spearman R.

\*Still significant after Bonferroni correction.

FIGURE 1 Estimate differences in FSH



**Figure 1** – Changes in mean follicle-stimulating hormone (FSH) serum levels from baseline to 6 and 12 months of degarelix treatment.

### FIGURE 2



2a



2b





**Figure 2** – Relationship between follicle-stimulating hormone (FSH) serum levels and fat body mass (FBM) (**Fig. 2a**), arm fat body mass (**Fig. 2b**), trunk fat body mass (**Fig. 2c**) and appendicular lean mass index (ALMI)/FBM ratio (**Fig. 2d**) after 12-months degarelix treatment.

R = Spearman correlation coefficient; p = p-value.

### CONSORT DIAGRAM (source data 123547 0 data set 3007640 s1333z.xls)

